FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?
GHAPPcast15 Juli 2025

FAQ: What Is the Significance of Alarm Symptoms Including Pathophysiology?

Thank you to Ardelyx for your support on this FAQ video module.

In this episode, Kristina Skarbinski, a seasoned GI nurse practitioner based in Boston, shares essential insights on identifying alarm symptoms that may help distinguish Irritable Bowel Syndrome (IBS) from more serious gastrointestinal conditions. While IBS is a common functional disorder, it’s critical to recognize red flag symptoms that require further evaluation before making a diagnosis. Christina walks through key warning signs, including rectal bleeding, melena (black tarry stools), nocturnal bowel movements, progressive abdominal pain, unexplained weight loss, and anemia. She also explains the significance of an elevated fecal calprotectin level and the importance of family history in assessing the risk for colorectal cancer or inflammatory bowel disease (IBD). Patients over 50 should be up to date on colon cancer screening, especially when symptoms are new or worsening. If no alarm features are present, clinicians can confidently proceed with IBS evaluation using the Rome IV criteria and symptom-based testing. This educational overview offers a practical guide for primary care and GI professionals. Learn more by visiting the GHAPP website or the ACE App for additional clinical resources.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(154)

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease

Thank you to Salix for the support on this FAQ Video Module.This educational FAQ module, featuring Mikhail Alper, PA-C focuses on recognizing risk factors and early clinical indicators of Overt Hepati...

26 Maj 2min

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease

Thank you to Johnson & Johnson for the support on this FAQ Video Module.This FAQ video features Janette Villalon, PA, who reviews the role of guselkumab in treating extraintestinal manifestations in p...

19 Maj 5min

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the evolving role of monotherapy versus combination therapy in the treatment of inflammato...

14 Maj 3min

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Medication Review: Stable PK Supporting Continuous Inflammatory Control

Thank you to Celltrion for the support on this Medication Review Video Module.This medication review explores the role of stable pharmacokinetics (PK) in achieving continuous inflammatory control in i...

7 Maj 6min

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab

Thank you to Johnson & Johnson for the support on this Journal Club Review Module.In this journal club video, Sharon Dudley Brown, CRNP, PhD, from the IBD Center at Johns Hopkins University, reviews t...

28 Apr 5min

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD

Thank you to AbbVie for the support on this Journal Club Review Module.This journal club review episode explores the benefit–risk profile of Upadacitinib for patients with moderately to severely activ...

21 Apr 23min

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments?

Learn how to effectively support patients starting treatment for MASH with this practical, clinician-focused discussion featuring expert advanced practice providers. In this episode, hepatology specia...

14 Apr 18min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-missbruk-medberoende-2
inga-beiga-morsor
rss-vuxna-pa-latsas
angestpodden
sexnoveller-deluxe
johannes-hansen-podcast
sova-med-dan-horning
rss-viktmedicinpodden
not-fanny-anymore
rss-jossan-nina
sa-in-i-sjalen
rss-basta-livet
brottarbroder
tyngre-radio
sex-pa-riktigt-med-marika-smith
rss-relationsrevolutionen
smartare-fitness-podden
halsoveckan-by-tyngre
giggles-med-wiggles